INTRODUCTION
============

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly emerged since December 2019. As of May 24, 2020, a total of 5,204,508 confirmed cases, including 337,687 deaths, have been reported worldwide.[@B1] Despite the introduction of social distancing to slow the spread in many countries, the outbreak of COVID-19 has overwhelmed healthcare systems in several countries. Inadequate medical resources have warranted the identification of risk factors for the diagnosis and severity of COVID-19. Although early epidemiological studies from China reported the prevalence of comorbidities,[@B2][@B3] and its association with disease severity,[@B4][@B5] the host factors that increase the risk of COVID-19 infection or its severity still need to be identified.

The national health insurance service of Korea registered approximately all COVID-19 patients and test negative controls within the national insurance system. Recently, the Health Insurance Review & Assessment Service (HIRA) of Korea agreed to the share invaluable national health insurance claims data related to COVID-19 for public health purposes. This data is useful for the identification of underlying comorbidities which are associated with the diagnosis and severity of COVID-19.

We conducted a retrospective case-control study, examining the effect of various underlying comorbidities on the risk of infection and severity of COVID-19 using data from the nationwide medical insurance claim database in Korea.

METHODS
=======

Data source
-----------

We extracted data from the insurance claims database of the HIRA of Korea. The claims ([Fig. 1](#F1){ref-type="fig"})[@B6] are made with a special "public crisis" code (MT043) under the national insurance coverage for every suspected case. The reimbursement for confirmed cases is claimed with the Korean Standard Classification of Diseases and Causes of Death, 7th edition (KCD-7) codes, which is a modified version of the International Classification of Diseases and Related Health Problems, 10th edition (ICD-10), designated for COVID-19. Thus, we identified all tested individuals within the national health insurance coverage using the code MT043. All subjects with KCD-7 codes for COVID-19 were categorized as reverse transcription polymerase chain reaction (RT-PCR) test-positive cases when the diagnosis was confirmed using RT-PCR with respiratory tract specimens, all RT-PCR positive subjects were identified as a confirmed cases using the database of Korean Center for Disease Control (KCDC); the remaining subjects were categorized as controls ("RT-PCR test-negative" controls). Moreover, severe cases were defined as patients with a diagnosis confirmed by an RT-PCR test, who had claim data for oxygen therapy, mechanical ventilator, extracorporeal membrane oxygenation, and cardiopulmonary resuscitation. The remaining laboratory confirmed subjects were categorized as non-severe cases ([Fig. 2](#F2){ref-type="fig"}).

![Overview of national health insurance claims data from Health Insurance Review & Assessment Service of Korea (Redrawn from Jung et al. *Sci Rep* 2019;19(1):8750).[@B6]](jkms-35-e237-g001){#F1}

![Flow chart of selecting process for study participants.\
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Study design and definitions
----------------------------

This was a two-staged retrospective case-control study that evaluated the underlying comorbidities associated with the diagnosis and severity of COVID-19. First, we examined the underlying comorbidities associated with the diagnosis of COVID-19 between laboratory confirmed cases and test-negative controls. In addition, the underlying comorbidities associated with the severity of COVID-19 were evaluated and compared between the severe and non-severe confirmed cases. Underlying comorbidities were defined as the reimbursement for ≥ 2 times of KCD-7 code of study diseases, within 3 years prior to the test for COVID-19. The disease of interest was selected from the list of ICD-10 mapping tree, with reports of possible association with SARS-CoV-2 in previous epidemiologic studies, and those with theoretical concerns for increased risk ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). Two authors reviewed the literature and selected the diseases of interest, and disagreement was arbitrated by the third author. There were 56 categories in the disease group ([Supplementary Table 2](#S2){ref-type="supplementary-material"}). The location of the medical institution where the patients were treated was identified to control a substantially higher risk of community acquired infection. Daegu city and Gyeongsangbuk-do province (DG) had large regional outbreaks, and many cases did not have any identifiable contact trace.[@B7] A subgroup analysis was conducted for DG area and outside of DG area to identify the risk factors related to community outbreaks. Also, Charlson comorbidity index (CCI) was calculated as previously described ([Supplementary Table 3](#S3){ref-type="supplementary-material"}).[@B8] Healthcare utilization was evaluated by the number of hospitalizations, number of outpatient visits, and number of emergency room visits within one year prior to tests for COVID-19. The analysis codes for this study was presented in [Supplementary Data 1](#S10){ref-type="supplementary-material"}.

Statistical analysis
--------------------

The baseline characteristics of cases and controls were compared using the χ^2^ test and Student\'s *t*-test, as appropriate. The prevalence of comorbidities was compared using logistic regression models adjusted for sex, age, residence, CCI, and healthcare utilization as covariates. To mitigate the risk of quasi-separation and overfitting, we performed two different types of multivariate analysis. The multivariate model 1 included one comorbidity at a time with all other covariates, constructing individual models for each comorbidity; the multivariate model 2, included all comorbidities and other covariates in a single model. We used the significance threshold of *P* \< 0.05, and all tests were two-tailed. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for the analyses.

Ethics statement
----------------

This study was approved by the Institutional Review Board (IRB) of the Gil Medical Center, Gachon University College of Medicine which provided a waiver of consent (GFIRB2020-134). The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

RESULTS
=======

Baseline demographics between case- and test-negative controls
--------------------------------------------------------------

At the data cutoff time on May 15, 2020, a total of 219,961 individuals aged ≥ 18 years, who underwent laboratory tests for COVID-19 in Korea were identified and analyzed. The proportion of female was slightly higher (4,371 of 7,341; 59.5%) than that of male in the case group. More than half of COVID-19 patients (4,027 of 7,341; 54.9%) were treated in medical facilities in the DG area, while 45.1% of confirmed cases, treated outside of the DG area. The control group showed higher healthcare utilization within 1 year before undergoing laboratory tests for COVID-19. Overall, the case group showed a lower prevalence than that of the control group, except for schizophrenia, mental retardation, and developmental disorders ([Table 1](#T1){ref-type="table"}).

###### Baseline demographics and prevalence of comorbidities between case and test negative controls

![](jkms-35-e237-i001)

  Variables                                                            Cases (n = 7,341)                           Controls (n = 212,620)                                     *P* value                         
  -------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------- ---------------- ---------------- ----------
  Demographic characteristics                                                                                                                                                                                   
                                                                       Sex, male                                   2,970 (40.5)                                               101,361 (47.7)   \< 0.001         
                                                                       Age, yr                                     47.05 ± 19.0                                               49.48 ± 19.9     \< 0.001         
                                                                                                                   18--49                                                     3,819 (52.0)     113,734 (53.5)   
                                                                                                                   50--64                                                     2,159 (29.4)     44,652 (21.0)    
                                                                                                                   65--79                                                     992 (13.5)       34,080 (16.0)    
                                                                                                                   ≥ 80                                                       373 (5.1)        20,154 (9.5)     
                                                                       Residence                                                                                                                                
                                                                                                                   DG area                                                    4,027 (54.9)     31,259 (14.7)    \< 0.001
                                                                                                                   Except DG                                                  3,314 (45.1)     181,361 (85.3)   
                                                                       Charlson comorbidity index                  1.23 ± 1.6                                                 1.94 ± 2.4       \< 0.001         
  Healthcare utilization within 1 years before diagnosis of COVID-19                                                                                                                                            
                                                                       No. of hospitalization                      0.25 ± 0.9                                                 0.83 ± 2.1       \< 0.001         
                                                                       No. of outpatient visit                     17.19 ± 21.4                                               25.46 ± 31.9     \< 0.001         
                                                                       No. of ED visit                             0.12 ± 0.5                                                 0.44 ± 1.6       \< 0.001         
                                                                       Medical aids                                619 (8.4)                                                  12,031 (5.7)     \< 0.001         
  Underlying diseases                                                                                                                                                                                           
                                                                       Endocrinopathy                                                                                                                           
                                                                                                                   Diabetes                                                   1,043 (14.2)     39,037 (18.4)    \< 0.001
                                                                                                                   Thyroid disease                                            434 (5.9)        13,491 (6.4)     0.134
                                                                                                                   Cushing syndrome                                           2 (0.03)         215 (0.1)        0.047
                                                                                                                   Osteoporosis                                               633 (8.6)        20,467 (9.6)     0.004
                                                                       Cardiac disease                                                                                                                          
                                                                                                                   Isolated hypertension                                      1,628 (22.2)     64,412 (30.3)    \< 0.001
                                                                                                                   Ischemic heart disease                                     306 (4.2)        18,971 (8.9)     \< 0.001
                                                                                                                   Heart failure and cardiomyopathy                           266 (3.62)       13,881 (6.5)     \< 0.001
                                                                                                                   Valvular heart disease                                     28 (0.4)         1,960 (0.9)      \< 0.001
                                                                                                                   Cardiac arrhythmia                                         201 (2.7)        11,517 (5.4)     \< 0.001
                                                                       Chronic respiratory disease                                                                                                              
                                                                                                                   Chronic upper respiratory disease                          4,430 (60.4)     140,924 (66.3)   \< 0.001
                                                                                                                   Chronic lower respiratory disease                          1,639 (22.3)     72,058 (33.9)    \< 0.001
                                                                                                                   Environmental lung disease                                 11 (0.2)         1,267 (0.6)      \< 0.001
                                                                                                                   Interstitial lung disease                                  12 (0.2)         1,580 (0.7)      \< 0.001
                                                                                                                   Chronic respiratory failure and diaphragm palsy            1 (0.01)         261 (0.1)        0.008
                                                                                                                   Pulmonary vascular disease                                 11 (0.2)         1,279 (0.6)      \< 0.001
                                                                       Renal disease and ESRD                                                                                                                   
                                                                                                                   Hypertensive renal disease                                 19 (0.3)         1,611 (0.8)      \< 0.001
                                                                                                                   Glomerular disease                                         76 (1.0)         3,690 (1.7)      \< 0.001
                                                                                                                   Renal tubule-interstitial disease                          37 (0.5)         1,811 (0.9)      0.001
                                                                                                                   History of acute renal failure                             6 (0.1)          2,282 (1.1)      \< 0.001
                                                                                                                   Chronic renal failure and ESRD                             72 (1.0)         9,149 (4.3)      \< 0.001
                                                                                                                   Urolithiasis                                               85 (1.2)         3,814 (1.8)      \< 0.001
                                                                       Viral hepatitis and chronic liver disease                                                                                                
                                                                                                                   HBV, acute and chronic                                     115 (1.6)        4,387 (2.1)      0.003
                                                                                                                   HCV, acute and chronic                                     17 (0.2)         954 (0.5)        0.006
                                                                                                                   Non-B, non-C hepatitis                                     612 (8.3)        22,196 (10.4)    \< 0.001
                                                                                                                   Liver cirrhosis                                            44 (0.6)         3,833 (1.8)      \< 0.001
                                                                                                                   Hepatic failure                                            6 (0.1)          751 (0.4)        \< 0.001
                                                                       Disease of digestive system                                                                                                              
                                                                                                                   Non-infectious disease of upper digestive system           6,388 (87.0)     196,527 (92.4)   \< 0.001
                                                                                                                   Non-infectious disease of lower digestive system           2,013 (27.4)     80,096 (37.7)    \< 0.001
                                                                                                                   Pancreatic disease                                         40 (0.5)         4,933 (2.3)      \< 0.001
                                                                                                                   Biliary disease                                            129 (1.8)        9,813 (4.6)      \< 0.001
                                                                       Chronic neurologic disease                                                                                                               
                                                                                                                   Systemic atrophy                                           3 (0.04)         320 (0.2)        0.016
                                                                                                                   Parkinsonism and movement disorder                         265 (3.6)        8,890 (4.2)      0.016
                                                                                                                   Alzheimer and degenerative disease                         207 (2.8)        9,266 (4.4)      \< 0.001
                                                                                                                   Multiple sclerosis                                         6 (0.08)         190 (0.09)       0.830
                                                                                                                   Epilepsy                                                   131 (1.8)        6,776 (3.2)      \< 0.001
                                                                                                                   Transient cerebral ischemia, stroke, cerebral hemorrhage   487 (6.6)        22,223 (10.5)    \< 0.001
                                                                                                                   Dementia                                                   368 (5.0)        13,809 (6.5)     \< 0.001
                                                                       Malignancy                                                                                                                               
                                                                                                                   Solid organ, except respiratory, thyroid                   223 (3.0)        18,556 (8.7)     \< 0.001
                                                                                                                   Respiratory tract                                          28 (0.4)         3,822 (1.8)      \< 0.001
                                                                                                                   Thyroid cancer                                             80 (1.1)         2,473 (1.2)      0.564
                                                                                                                   Hematologic                                                8 (0.1)          1,731 (0.8)      \< 0.001
                                                                       Rheumatologic disease                                                                                                                    
                                                                                                                   Rheumatoid arthritis                                       186 (2.5)        5,853 (2.8)      0.259
                                                                                                                   SLE                                                        0 (0.0)          0 (0.0)          
                                                                                                                   Systemic connective tissue disease                         39 (0.5)         2,410 (1.1)      \< 0.001
                                                                       Hematologic disease                                                                                                                      
                                                                                                                   Anemia                                                     505 (6.9)        26,462 (12.5)    \< 0.001
                                                                                                                   Coagulopathy                                               35 (0.5)         2,839 (1.3)      \< 0.001
                                                                                                                   Bone marrow dysfunction                                    24 (0.3)         2,298 (1.1)      \< 0.001
                                                                       Obesity                                     3 (0.04)                                                   339 (0.2)        0.011            
                                                                       Nutritional deficiency                      287 (3.9)                                                  15,128 (7.1)     \< 0.001         
                                                                       Mental and Behavioral disorders                                                                                                          
                                                                                                                   Substance use                                              86 (1.2)         2,504 (1.2)      0.962
                                                                                                                   Schizophrenia                                              263 (3.6)        4,717 (2.2)      \< 0.001
                                                                                                                   Mood disorder                                              769 (10.8)       31,575 (14.9)    \< 0.001
                                                                                                                   Neurosis                                                   931 (12.7)       36,488 (17.2)    \< 0.001
                                                                                                                   Personality disorder                                       13 (0.2)         415 (0.2)        0.729
                                                                                                                   Mental retardation, development disorder                   37 (0.5)         542 (0.3)        \< 0.001
                                                                       Immune deficiency, HIV infection            4 (0.1)                                                    320 (0.2)        0.035            

Data are presented as mean **±** standard deviation or number (%).

DG = Daegu city and Gyeongsangbuk-do province area, COVID-19 = coronavirus disease 2019, ED = emergency department, ESRD = end-stage renal disease, HBV = hepatitis B virus, HCV = hepatitis C virus, SLE = systemic lupus erythematosus, HIV = human immunodeficiency virus.

Comorbidities associated with diagnosis of COVID-19
---------------------------------------------------

### Result of overall analysis

[Fig. 3](#F3){ref-type="fig"} and [Supplementary Table 4](#S4){ref-type="supplementary-material"} represent the odds ratios (ORs) for the diagnosis of COVID-19 according to the 56 categories of comorbidities. Schizophrenia, mental retardation, and developmental disorders were associated with an increased risk of COVID-19 in univariate analysis. In terms of multivariate analysis, diabetes (odds ratio range \[ORR\], 1.206--1.254), osteoporosis (ORR, 1.128--1.157), rheumatoid arthritis (ORR, 1.207--1.244), substance use (ORR, 1.321--1.381), and schizophrenia (ORR, 1.614--1.721) showed an increased risk in the whole study population ([Supplementary Table 4](#S4){ref-type="supplementary-material"}). Non-insulin dependent diabetes mellitus (NIDDM) (ORR, 1.182--1.278), mental retardation and developmental disorder (OR, 1.511; 95% confidential interval \[CI\], 1.051--2.173) showed an increased risk only in multivariate analysis with single disease category. Ischemic heart disease (ORR, 0.789--0.803), chronic lower respiratory disease (ORR, 0.772--0.778), interstitial lung disease (ORR, 0.494--0.547), history of acute renal failure (ARF) (ORR, 0.222--0.284), chronic renal failure (CRF) and end-stage renal disease (ESRD) (ORR, 0.503--0.505), liver cirrhosis (ORR, 0.633--0.656), non-infectious upper digestive system disease (ORR, 0.683--0.720), non-infectious lower digestive system diseases (ORR, 0.841--0.884), pancreatic disease (ORR, 0.473--0.531), biliary disease (ORR, 0.611--0.669), epilepsy (ORR, 0.738--0.786), transient cerebral ischemia, stroke, hemorrhage (ORR, 0.821--0.853), solid organ malignancy (ORR, 0.682--0.748), hematologic malignancy (ORR, 0.353--0.393), systemic connective tissue disease (ORR, 0.647--0.679), anemia (ORR, 0.789--0.854), and neurosis (ORR, 0.894--0.919) showed a decreased risk of COVID-19 in whole multivariate analysis.

![Analysis of relationship between comorbidities and infection of COVID-19.\
COVID-19 = coronavirus disease 2019, N/A = not applicable, IDDN = insulin-dependent diabetes mellitus, NIDDM = non-insulin dependent diabetes mellitus, ESRD = end-stage renal disease, OR = odds ratio.](jkms-35-e237-g003){#F3}

### Analysis of subgroup which excluded high regional outbreak area (DG area)

The case group showed a lower prevalence than that of the control group in most disease categories ([Supplementary Table 5](#S5){ref-type="supplementary-material"}). NIDDM without complication (OR, 1.170; 95% CI, 1.005--1.362) showed an increased risk only in multivariate analysis with single disease category, while rheumatoid arthritis (ORR, 1.335--1.400) showed an increased risk in whole multivariate analysis ([Fig. 3](#F3){ref-type="fig"}). Cardiac arrhythmia (ORR, 0.536--0.590), chronic upper respiratory diseases (ORR, 0.793--0.903), dementia (ORR, 0.621--0.734), and mood disorder (ORR, 0.760--0.824) additionally showed a decreased risk of COVID-19 in multivariate analysis of this subgroup. The other overall pattern of association was consistent with the whole group analysis except ischemic heart disease, history of ARF, liver cirrhosis, epilepsy, systemic connective tissue diseases, and neurosis.

### Analysis of subpopulation in high regional outbreak area (DG area)

This subpopulation analysis was conducted to identify the risk factors for high regional outbreak areas. Substance use, schizophrenia, mental retardation, and developmental disorder were associated with an increased risk of COVID-19 in univariate analysis. Diabetes (ORR, 1.255--1.314), substance use (ORR, 1.680--1.750), schizophrenia (ORR, 2.178--2.245), mental retardation and developmental disorder (ORR, 1.668--1.943) were associated with an increased risk of COVID-19 outbreak in whole multivariate analysis, while chronic upper respiratory diseases (ORR, 1.160--1.162), glomerular diseases (ORR, 1.372--1.381) was associated with an increased risk of COVID-19 only in multivariate analysis with all comorbidities ([Fig. 3](#F3){ref-type="fig"} and [Supplementary Table 6](#S6){ref-type="supplementary-material"}). The disease categories which showed a decreased risk of COVID-19 were consistent with whole group analysis except interstitial lung diseases, respiratory malignancy, hematologic malignancy, and systemic connective tissue diseases.

Baseline demographics between severe and non-severe confirmed COVID-19
----------------------------------------------------------------------

Severe cases accounted for 13.0% (954 of 7,341) of the laboratory confirmed cases. The mean age was 67.01 (standard deviation, 15.1), and 48.0% (458 of 954) of the patients in the severe group were male. The severe group had relatively older patients, The proportion of Daegu/Gyeongbuk area (DG area, 74.4%, 710 of 954), median CCI, the number of healthcare utilization, and the prevalence of comorbidities were higher in the severe group than in the non-severe group ([Table 2](#T2){ref-type="table"}).

###### Baseline demographics and prevalence of comorbidities between severe and non-severe laboratory confirmed COVID-19
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  Variables                                                            Severe (n = 954)                            Non-severe (n = 6,387)                                     *P* value                     
  -------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------- -------------- -------------- ----------
  Demographic characteristics                                                                                                                                                                               
                                                                       Sex, male                                   458 (48.1)                                                 2,512 (39.3)   \< 0.001       
                                                                       Age, yr                                     67.01 ± 15.1                                               44.07 ± 17.7   \< 0.001       
                                                                                                                   18--49                                                     99 (10.4)      3,720 (58.2)   
                                                                                                                   50--64                                                     295 (30.9)     1,862 (29.2)   
                                                                                                                   65--79                                                     350 (36.7)     642 (10.1)     
                                                                                                                   ≥ 80                                                       210 (22.0)     163 (2.6)      
                                                                       Residence                                                                                                                            
                                                                                                                   DG area                                                    710 (74.4)     3,317 (51.9)   \< 0.001
                                                                                                                   Except DG                                                  244 (25.6)     3,070 (48.1)   
                                                                       Charlson comorbidity index                  2.68 ± 2.2                                                 1.01 ± 1.4     \< 0.001       
  Healthcare utilization within 1 years before diagnosis of COVID-19                                                                                                                                        
                                                                       No. of hospitalization                      0.67 ± 1.5                                                 0.19 ± 0.8     \< 0.001       
                                                                       No. of outpatient visit                     29.44 ± 35.3                                               15.36 ± 17.7   \< 0.001       
                                                                       No. of ED visit                             0.25 ± 0.7                                                 0.10 ± 0.4     \< 0.001       
                                                                       Medical aids                                120 (12.6)                                                 499 (7.8)      \< 0.001       
  Underlying diseases                                                                                                                                                                                       
                                                                       Endocrinopathy                                                                                                                       
                                                                                                                   Diabetes                                                   346 (36.3)     697 (10.9)     \< 0.001
                                                                                                                   Thyroid disease                                            89 (9.3)       345 (5.4)      \< 0.001
                                                                                                                   Cushing syndrome                                           1 (0.1)        1 (0.02)       0.120
                                                                                                                   Osteoporosis                                               184 (19.3)     449 (7.0)      \< 0.001
                                                                       Cardiac disease                                                                                                                      
                                                                                                                   Isolated hypertension                                      531 (55.7)     1,097 (17.2)   \< 0.001
                                                                                                                   Ischemic heart disease                                     115 (12.1)     191 (3.0)      \< 0.001
                                                                                                                   Heart failure and cardiomyopathy                           131 (13.7)     135 (2.1)      \< 0.001
                                                                                                                   Valvular heart disease                                     9 (0.9)        19 (0.3)       0.007
                                                                                                                   Cardiac arrhythmia                                         84 (8.8)       117 (1.8)      \< 0.001
                                                                       Chronic respiratory disease                                                                                                          
                                                                                                                   Chronic upper respiratory disease                          589 (61.7)     3,841 (60.1)   0.345
                                                                                                                   Chronic lower respiratory disease                          364 (38.2)     1,275 (20.0)   \< 0.001
                                                                                                                   Environmental lung disease                                 7 (0.7)        4 (0.1)        \< 0.001
                                                                                                                   Interstitial lung disease                                  10 (1.1)       2 (0.03)       \< 0.001
                                                                                                                   Chronic respiratory failure and diaphragm palsy            0 (0.0)        1 (0.02)       1.000
                                                                                                                   Pulmonary vascular disease                                 4 (0.4)        7 (0.1)        0.044
                                                                       Renal disease and ESRD                                                                                                               
                                                                                                                   Hypertensive renal disease                                 7 (0.7)        12 (0.2)       0.008
                                                                                                                   Glomerular disease                                         22 (2.3)       54 (0.9)       \< 0.001
                                                                                                                   Renal tubule-interstitial disease                          12 (1.3)       25 (0.4)       0.002
                                                                                                                   History of acute renal failure                             0 (0.0)        6 (0.1)        1.000
                                                                                                                   Chronic renal failure and ESRD                             39 (4.1)       33 (0.5)       \< 0.001
                                                                                                                   Urolithiasis                                               19 (2.0)       66 (1.0)       0.010
                                                                       Viral hepatitis and chronic liver disease                                                                                            
                                                                                                                   HBV, acute and chronic                                     26 (2.7)       89 (1.4)       0.002
                                                                                                                   HCV, acute and chronic                                     4 (0.4)        13 (0.2)       0.264
                                                                                                                   Non-B, non-C hepatitis                                     129 (13.5)     483 (7.6)      \< 0.001
                                                                                                                   Liver cirrhosis                                            14 (1.5)       30 (0.5)       \< 0.001
                                                                                                                   Hepatic failure                                            2 (0.2)        4 (0.1)        0.178
                                                                       Disease of digestive system                                                                                                          
                                                                                                                   Non-infectious disease of upper digestive system           879 (92.1)     5,509 (86.3)   \< 0.001
                                                                                                                   Non-infectious disease of lower digestive system           418 (43.8)     1,595 (25.0)   \< 0.001
                                                                                                                   Pancreatic disease                                         6 (0.6)        34 (0.5)       0.705
                                                                                                                   Biliary disease                                            42 (4.4)       87 (1.4)       \< 0.001
                                                                       Chronic neurologic disease                                                                                                           
                                                                                                                   Systemic atrophy                                           0 (0.0)        3 (0.1)        1.000
                                                                                                                   Parkinsonism and movement disorder                         72 (7.6)       193 (3.0)      \< 0.001
                                                                                                                   Alzheimer and degenerative disease                         70 (7.3)       137 (2.1)      \< 0.001
                                                                                                                   Multiple sclerosis                                         2 (0.2)        4 (0.1)        0.178
                                                                                                                   Epilepsy                                                   35 (3.7)       96 (1.5)       \< 0.001
                                                                                                                   Transient cerebral ischemia, stroke, cerebral hemorrhage   184 (19.3)     303 (4.7)      \< 0.001
                                                                                                                   Dementia                                                   186 (19.5)     182 (2.9)      \< 0.001
                                                                       Malignancy                                                                                                                           
                                                                                                                   Solid organ, except respiratory, thyroid                   70 (7.3)       153 (2.4)      \< 0.001
                                                                                                                   Respiratory tract                                          15 (1.6)       13 (0.2)       \< 0.001
                                                                                                                   Thyroid cancer                                             12 (1.3)       68 (1.1)       0.592
                                                                                                                   Hematologic                                                2 (0.2)        6 (0.1)        0.279
                                                                       Rheumatologic disease                                                                                                                
                                                                                                                   Rheumatoid arthritis                                       33 (3.5)       153 (2.4)      0.051
                                                                                                                   SLE                                                        0 (0.0)        0 (0.0)        
                                                                                                                   Systemic connective tissue disease                         7 (0.7)        32 (0.5)       0.356
                                                                       Hematologic disease                                                                                                                  
                                                                                                                   Anemia                                                     140 (14.7)     365 (5.7)      \< 0.001
                                                                                                                   Coagulopathy                                               9 (0.9)        26 (0.4)       0.039
                                                                                                                   Bone marrow dysfunction                                    7 (0.7)        17 (0.3)       0.029
                                                                       Obesity                                     0 (0.0)                                                    3 (0.1)        1.000          
                                                                       Nutritional deficiency                      69 (7.2)                                                   218 (3.4)      \< 0.001       
                                                                       Mental and behavioral disorders                                                                                                      
                                                                                                                   Substance use                                              15 (1.6)       71 (1.0)       0.217
                                                                                                                   Schizophrenia                                              51 (5.4)       212 (3.3)      0.002
                                                                                                                   Mood disorder                                              203 (21.3)     593 (9.3)      \< 0.001
                                                                                                                   Neurosis                                                   228 (23.9)     703 (11.0)     \< 0.001
                                                                                                                   Personality disorder                                       5 (0.5)        8 (0.1)        0.019
                                                                                                                   Mental retardation, development disorder                   4 (0.4)        33 (0.5)       1.000
                                                                       Immune deficiency, HIV infection            1 (0.1)                                                    3 (0.1)        0.427          

Data are presented as mean **±** standard deviation or number (%).

DG = Daegu city and Gyeongsangbuk-do province area, COVID-19 = coronavirus disease 2019, ED = emergency department, ESRD = end-stage renal disease, HBV = hepatitis B virus, HCV = hepatitis C virus, SLE = systemic lupus erythematosus, HIV = human immunodeficiency virus.

Comorbidities associated with severity of COVID-19
--------------------------------------------------

### Result of overall analysis

The ORs for the severity of COVID-19 according to the 56 categories of comorbidities are shown in [Fig. 4](#F4){ref-type="fig"} and [Supplementary Table 7](#S7){ref-type="supplementary-material"}. Most disease categories except Cushing syndrome, chronic upper respiratory diseases, hepatitis C, hepatic failure, pancreatic diseases, multiple sclerosis, thyroid cancer, hematologic malignancy, rheumatoid arthritis, systemic connective tissue disease, substance use, mental retardation, and immune deficiency were associated with an increased risk of severe COVID-19 in univariate analysis. Isolated hypertension (ORR, 1.245--1.317), CRF and ESRD (ORR, 2.052--2.178) were significantly associated with an increased risk of severe COVID-19, while pancreatic diseases (ORR, 0.258--0.296), Alzheimer\'s and degenerative diseases (ORR, 0.693--0.701) were associated with a decreased risk of severe COVID-19 in all multivariate analysis. NIDDM without complication (ORR, 1.353--1.371), heart failure, and cardiomyopathy (ORR, 1.464--1.465), and cardiac arrhythmia (ORR, 1.400--1.405) showed an increased risk of severe COVID-19 in multivariate analysis with single disease category, while diabetes (OR, 1.247; 95% CI, 1.009--1.543), chronic respiratory diseases (ORR, 1.216--1.233) showed an increased risk of COVID-19 in multivariate analysis with all comorbidities.

![Analysis of relationship between comorbidities on severity of COVID-19.\
COVID-19 = coronavirus disease 2019, N/A = not applicable, IDDN = insulin-dependent diabetes mellitus, NIDDM = non-insulin dependent diabetes mellitus, ESRD = end-stage renal disease, OR = odds ratio.](jkms-35-e237-g004){#F4}

### Analysis of subpopulation which excluded high regional outbreak area (DG area)

In multivariate analysis, dementia (ORR, 2.440--3.471) was significantly associated with severe COVID-19 in all multivariate analysis, while diabetes (ORR, 1.522--1.620), bone marrow dysfunction (ORR, 6.748--9.259) showed an increased risk of severe disease only in multivariate analysis with all comorbidities ([Supplementary Table 8](#S8){ref-type="supplementary-material"}).

### Analysis of subpopulation in high regional outbreak area (DG area)

In multivariate analysis, the overall pattern of association was consistent with the whole group analysis except diabetes, heart failure and cardiomyopathy, and chronic lower respiratory disease ([Supplementary Table 9](#S9){ref-type="supplementary-material"}).

DISCUSSION
==========

In this study, we identified the possible comorbidities that might be associated with the risk of COVID-19 infection and its severity. Diabetes, osteoporosis, rheumatoid arthritis, substance use, and schizophrenia showed significant associations with the diagnosis of COVID-19. The patterns of comorbidities associated with the occurrence of COVID-19 might be different between high and non-high regional outbreak areas. Diabetes, chronic upper respiratory diseases, glomerular disease, substance use, schizophrenia, mental retardation, and developmental disorders were associated with community outbreak (DG area), whereas rheumatoid arthritis was associated with containment area (e.g., institutional outbreak). Diabetes, isolated hypertension, chronic lower respiratory disease, CRF, and ESRD were associated with severe COVID-19. Moreover, diabetes was strongly associated with the diagnosis and severity of COVID-19.

When interpreting the results of this study, it is necessary to consider the demographic differences between the case and control groups. Most diseases, except schizophrenia, mental retardation, and developmental disorders, showed a higher prevalence in the control group than in the case group ([Table 1](#T1){ref-type="table"}). This suggested that more tests for COVID-19 were performed in people at a risk of febrile respiratory illness, regardless of the COVID-19 pandemic.[@B9][@B10][@B11] Therefore, we presumed that the negative association in univariate analysis related to COVID-19 occurrence was based on biased baseline demographics and found that this selection bias was alleviated in the multivariate analysis ([Fig. 3](#F3){ref-type="fig"}). Moreover, we compared the laboratory confirmed cases to the RT-PCR-negative control groups and conducted subgroup analysis according to high regional outbreak areas where this bias would have been less affected. As a result, the comorbidities that increased the risk of diagnosis of COVID-19 were more meaningful. Therefore, we found that diabetes, osteoporosis, and rheumatoid arthritis might be risk factors for the diagnosis of COVID-19.

In the case of psychological disorders including substance use, schizophrenia, mental retardation, and developmental disorders, consideration as risk factors for COVID-19 was unjustifiable because this might be correlated with the large clustered outbreak in hospitalized patients who were admitted in closed wards for psychological treatment. Even considering these epidemiological characteristics, some early case reports on the COVID-19 outbreak suggested that differences in socioeconomic levels may influence SARS-CoV-2 infection.[@B12] It might be suggested that the accompanying low socioeconomic status might increase the risk of developing COVID-19 rather than schizophrenia or a psychological disorder itself.[@B13] This study also found that rheumatoid was associated with the diagnosis of COVID-19. Although the impact of immunosuppression on the diagnosis of COVID-19 remains unclear, it is suggested that the long-term use of steroids or immunosuppressants may increase susceptibility to COVID-19.

In spite of a potential selection bias, the result suggested the possibility of chronic illness including ischemic heart disease, cardiac arrhythmia, chronic upper and lower respiratory disease, chronic renal disease, liver cirrhosis, non-infectious upper and lower digestive disease, pancreatic disease, biliary disease, epilepsy, cerebrovascular disease, dementia, malignancy, systemic connective tissue, anemia, and neurosis being associated with a decreased risk of COVID-19. Patients with these conditions might have reduced social activity, which may reduce the possible risk of exposure to SARS-CoV-2. However, this is not clear, and more precise research is needed.

In early epidemiological studies of COVID-19, it was reported that comorbidities including diabetes, hypertension, and chronic respiratory disease, except for malignancy, were related to disease severity or death[@B4][@B5][@B14][@B15][@B16] as observed in this study. We also found that CRF and ESRD were significant risk factors for severe COVID-19. In addition, heart failure, cardiomyopathy, and cardiac arrhythmia might be associated with the severity of COVID-19. Human angiotensin-converting enzyme 2 (ACE2) is a functional receptor of SARS-CoV-2,[@B17] and the heart is a tissue rich in ACE receptors along with the lungs. Cases of COVID-19 related to myocarditis were reported in China[@B18] and Korea,[@B19] and myocarditis was also reported as a risk factor for severe COVID-19.[@B3]

In this study, pancreatic disease, Alzheimer\'s disease, and degenerative diseases were associated with a decreased risk of severe COVID-19. Although the detailed mechanism of this protective effect remains unclear, it is suggested that the possible protective effect may be attributable to drugs used to treat these diseases. For example, camostat mesylate which is widely used protease inhibitor in chronic pancreatic disease might have protective role in COVID-19. TMPRSS2 is a serine protease that primes the spike protein of human coronaviruses and facilitates its entry into the host cell.[@B20] Camostat mesylate was effective in SARS-CoV infected mouse model,[@B21] and it is suggested as a potential therapeutic option in COVID-19.[@B22][@B23]

This study has a few limitations. First, this study was limited to data from the nationwide claims database of subjects who underwent laboratory testing for COVID-19. Thus, the data of patients who were tested via "Drive Through" or local health centers and were treated at non-medical facilities was not included in this study. Therefore, the actual population affected by the disease was different from that of the analyzed population, which was used in this study. Despite this limitation, this study was conducted only for those who underwent the laboratory test for COVID-19 as per the insurance claims database. Therefore, the negative control group had a confirmed a negative result of SARS-CoV-2 infection. Thus, the comparison between this negative control group and case group helped in proper evaluation of the risk factors for COVID-19 occurrence. Another limitation was the inability of the data source to provide information on the severity of the comorbidities. Finally, we could not evaluate the detailed mechanism underlying the relationship between comorbidities and the diagnosis or severity of COVID-19. However, most comorbidities identified in each individual\'s health insurance claims data could be used for this study. It may be possible to discover previously unknown or unexpected risk factors based on a data driven approach.

In this retrospective case control study, we suggest that diabetes, osteoporosis, rheumatoid arthritis, disorder owing to substance use, and schizophrenia might be risk factors for COVID-19. Besides, hypertension, chronic lower respiratory disease, CRF, and ESRD are associated with severe COVID-19. In addition, diabetes is associated with the occurrence and severity of COVID-19.
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